Sign In
Buy AGIO
$30.02
-2.73 (-8.34%)
At Close: Jul 31, 2026
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO
04:34am, Wednesday, 03'rd Dec 2025
Fisher Asset Management LLC decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 8.5% during the undefined quarter, according to the company in its most recent disclosure with the S
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
01:36pm, Thursday, 20'th Nov 2025
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript
02:33pm, Wednesday, 19'th Nov 2025
Agios Pharmaceuticals, Inc. ( AGIO ) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST Company Participants Morgan Sanford Brian Go
Why Shares in Agios Pharmaceuticals Got Crushed Today
01:33pm, Wednesday, 19'th Nov 2025
Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026.
Why Is Agios Pharmaceuticals Stock Sinking Today?
12:30pm, Wednesday, 19'th Nov 2025
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.
Agios Pharma reports mixed results in late-stage study for sickle cell disease drug
08:24am, Wednesday, 19'th Nov 2025
Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
07:00am, Wednesday, 19'th Nov 2025
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did n
Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $57.25
02:54am, Tuesday, 04'th Nov 2025
Shares of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBe
Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones
01:47am, Tuesday, 04'th Nov 2025
Agios Pharmaceuticals delivered strong Q3'25 results, with revenue up 44% year-over-year and continued momentum in its rare-disease pipeline. AGIO's key catalysts include the FDA decision on Pyrukynd'
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
09:01am, Monday, 03'rd Nov 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
03:21pm, Friday, 31'st Oct 2025
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript
02:06pm, Thursday, 30'th Oct 2025
Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Morgan Sanford Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta M
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
08:40am, Thursday, 30'th Oct 2025
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to earnings of $4.2 per share a year ago.
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
06:30am, Thursday, 30'th Oct 2025
$12.9 million in third quarter PYRUKYND® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalasse
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
10:00am, Saturday, 18'th Oct 2025
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are ad
